Long-term outcome of patients with intermediate- and high-risk endometrial cancer after pelvic and paraaortic lymph node dissection: a comparison of laparoscopic vs. open procedure (2020) Papathemelis T, Oppermann H, Grafl S, Gerken M, Pauer A, Scharl S, Scharl A, et al. Journal article C-reactive protein as an early marker of immune-related adverse events (2019) Abolhassani AR, Schuler G, Kirchberger MC, Heinzerling L Journal article A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer (2019) Stubendorff B, Wilhelm K, Posselt K, Catto J, Hartmann A, Bertz S, Fuessel S, et al. Journal article Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy (2019) Danhof S, Strifler S, Hose D, Kortuem M, Bittrich M, Hefner J, Einsele H, et al. Journal article Loss of enhancer of zeste homologue 2 (EZH2) at tumor invasion front is correlated with higher aggressiveness in colorectal cancer cells (2019) Böhm J, Muenzner JK, Caliskan A, Ndreshkjana B, Erlenbach-Wünsch K, Merkel S, Croner R, et al. Journal article Is there a benefit of lymphadenectomy for overall and recurrence-free survival in type I FIGO IB G1-2 endometrial carcinoma? A retrospective population-based cohort analysis (2018) Papathemelis T, Hassas D, Gerken M, Klinkhammer-Schalke M, Scharl A, Lux MP, Beckmann M, Scharl S Journal article Can checkpoint inhibitor therapy improve response to chemotherapy? (2018) Kirchberger MC, Schilling B, Haferkamp S, Boßerhoff AK, Schuler G, Heinzerling L Journal article FOXM1 predicts disease progression in non-muscle invasive bladder cancer (2018) Rinaldetti S, Wirtz R, Worst TS, Hartmann A, Breyer J, Dyrskjot L, Erben P Journal article Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab (2017) Brueggemann C, Kirchberger MC, Goldinger SM, Weide B, Konrad A, Erdmann M, Schadendorf D, et al. Journal article A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO) (2017) Sehouli J, Tome O, Dimitrova D, Camara O, Runnebaum IB, Tessen HW, Rautenberg B, et al. Journal article